Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfisoxazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.81 |
| ▸ | EDNRB | P24530 | 9/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfisoxazole SCHEMBL23467 | 0.90 | EDNRA (1.00) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfisoxazole SCHEMBL788644 | 0.90 | EDNRA (1.00) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfisoxazole SCHEMBL5917298 | 0.88 | EDNRA (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfisoxazole SCHEMBL2200933 | 0.88 | EDNRA (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL3656 | 0.88 | ALDH1A1 (1.00) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL6896861 | 0.88 | ALDH1A1 (1.00) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL5870744 | 0.87 | ALDH1A1 (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL28565481 | 0.87 | ALDH1A1 (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL22467841 | 0.87 | ALDH1A1 (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 | |
| Sulfamethoxazole SCHEMBL1368068 | 0.87 | ALDH1A1 (0.97) | EDNRAEDNRBADRA1ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1545613-A4 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007103288-A2 | ENGINEERED ANTIBODY DRUG CONJUGATES | SEATTLE GENETICS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| EP-1725249-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | Seattle Genetics, Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005081711-A2 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1545613-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | Seattle Genetics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004010957-A2 | DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1124581-A1 | TRANSDERMAL DELIVERY OF MEDICATIONS USING A COMBINATION OF PENETRATION ENHANCERS | Grasela, John C. (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000025822-A1 | TRANSDERMAL DELIVERY OF MEDICATIONS USING A COMBINATION OF PENETRATION ENHANCERS | GRASELA JOHN C (US) | 2000-05-11 | — | — | WO | disclosed |
| WO-1996020010-A1 | COMBINATION FOR REDUCING ANTIMICROBIAL RESISTANCE USING A METHYLATION INHIBITOR IN COMBINATION WITH AN ANTIBIOTIC | ORIDIGM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |